Risk of Rupture After Intracranial Aneurysm Growth.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 10 2021
Historique:
pubmed: 31 8 2021
medline: 15 1 2022
entrez: 30 8 2021
Statut: ppublish

Résumé

Unruptured intracranial aneurysms not undergoing preventive endovascular or neurosurgical treatment are often monitored radiologically to detect aneurysm growth, which is associated with an increase in risk of rupture. However, the absolute risk of aneurysm rupture after detection of growth remains unclear. To determine the absolute risk of rupture of an aneurysm after detection of growth during follow-up and to develop a prediction model for rupture. Individual patient data were obtained from 15 international cohorts. Patients 18 years and older who had follow-up imaging for at least 1 untreated unruptured intracranial aneurysm with growth detected at follow-up imaging and with 1 day or longer of follow-up after growth were included. Fusiform or arteriovenous malformation-related aneurysms were excluded. Of the 5166 eligible patients who had follow-up imaging for intracranial aneurysms, 4827 were excluded because no aneurysm growth was detected, and 27 were excluded because they had less than 1 day follow-up after detection of growth. All included aneurysms had growth, defined as 1 mm or greater increase in 1 direction at follow-up imaging. The primary outcome was aneurysm rupture. The absolute risk of rupture was measured with the Kaplan-Meier estimate at 3 time points (6 months, 1 year, and 2 years) after initial growth. Cox proportional hazards regression was used to identify predictors of rupture after growth detection. A total of 312 patients were included (223 [71%] were women; mean [SD] age, 61 [12] years) with 329 aneurysms with growth. During 864 aneurysm-years of follow-up, 25 (7.6%) of these aneurysms ruptured. The absolute risk of rupture after growth was 2.9% (95% CI, 0.9-4.9) at 6 months, 4.3% (95% CI, 1.9-6.7) at 1 year, and 6.0% (95% CI, 2.9-9.1) at 2 years. In multivariable analyses, predictors of rupture were size (7 mm or larger hazard ratio, 3.1; 95% CI, 1.4-7.2), shape (irregular hazard ratio, 2.9; 95% CI, 1.3-6.5), and site (middle cerebral artery hazard ratio, 3.6; 95% CI, 0.8-16.3; anterior cerebral artery, posterior communicating artery, or posterior circulation hazard ratio, 2.8; 95% CI, 0.6-13.0). In the triple-S (size, site, shape) prediction model, the 1-year risk of rupture ranged from 2.1% to 10.6%. Within 1 year after growth detection, rupture occurred in approximately 1 of 25 aneurysms. The triple-S risk prediction model can be used to estimate absolute risk of rupture for the initial period after detection of growth.

Identifiants

pubmed: 34459846
pii: 2783663
doi: 10.1001/jamaneurol.2021.2915
pmc: PMC8406207
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1228-1235

Commentaires et corrections

Type : ErratumIn

Auteurs

Laura T van der Kamp (LT)

Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, University Medical Center Utrecht, Utrecht, the Netherlands.

Gabriel J E Rinkel (GJE)

Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, University Medical Center Utrecht, Utrecht, the Netherlands.

Dagmar Verbaan (D)

Department of Neurosurgery, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

René van den Berg (R)

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

W Peter Vandertop (WP)

Department of Neurosurgery, Amsterdam University Medical Centers, Amsterdam, the Netherlands.

Yuichi Murayama (Y)

Department of Neurosurgery, the Jikei University School of Medicine, Tokyo, Japan.

Toshihiro Ishibashi (T)

Department of Neurosurgery, the Jikei University School of Medicine, Tokyo, Japan.

Antti Lindgren (A)

Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland.
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.

Timo Koivisto (T)

Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.
Department of Neurosurgery, Kuopio University Hospital, Kuopio, Finland.

Mario Teo (M)

Department of Neurosurgery, Institute of Neurological Science, Glasgow, United Kingdom.

Jerome St George (J)

Department of Neurosurgery, Institute of Neurological Science, Glasgow, United Kingdom.

Ronit Agid (R)

Division of Neuroradiology, Joint Department of Medical Imaging and Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

Ivan Radovanovic (I)

Division of Neuroradiology, Joint Department of Medical Imaging and Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.

Junta Moroi (J)

Department of Surgical Neurology, Akita Cerebrospinal and Cardiovascular Center, Akita, Japan.

Keiji Igase (K)

Department of Advanced Neurosurgery, Ehime University Graduate School of Medicine, Toon City, Ehime, Japan.

Ido R van den Wijngaard (IR)

Department of Neurology, Haaglanden Medical Center, the Hague, the Netherlands.

Melissa Rahi (M)

Clinical Neurosciences, University of Turku, Turku, Finland.
Department of Neurosurgery, Neurocenter, Turku University Hospital, Turku, Finland.

Jaakko Rinne (J)

Clinical Neurosciences, University of Turku, Turku, Finland.
Department of Neurosurgery, Neurocenter, Turku University Hospital, Turku, Finland.

Johanna Kuhmonen (J)

Clinical Neurosciences, University of Turku, Turku, Finland.
Department of Neurosurgery, Neurocenter, Turku University Hospital, Turku, Finland.

Hieronymus D Boogaarts (HD)

Department of Neurosurgery, Radboud University Medical Center, Nijmegen, the Netherlands.

George K C Wong (GKC)

Department of Surgery, Prince of Wales Hospital, Hong Kong, China.

Jill M Abrigo (JM)

Department of Imaging and Interventional Radiology, Basement, Yue Kong Pao Centre for Cancer and the Lady Pao Children's Cancer Centre, Prince of Wales Hospital, Hong Kong, China.

Akio Morita (A)

Department of Neurological Surgery, Nippon Medical School, Tokyo, Japan.

Yoshiaki Shiokawa (Y)

Department of Neurosurgery, Kyorin University, Tokyo, Japan.

Katharina A M Hackenberg (KAM)

Department of Neurosurgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.

Nima Etminan (N)

Department of Neurosurgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany.

Irene C van der Schaaf (IC)

Department of Radiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Nicolaas P A Zuithoff (NPA)

Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.

Mervyn D I Vergouwen (MDI)

Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, University Medical Center Utrecht, Utrecht, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH